Implement Effective Medical Affairs Launch Strategies

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Interweaving Medical Strategy to Maximize New Treatment Success: Developing and Operationalizing Effective Launch Strategies”

STUDY OVERVIEW

Medical Affairs teams play a pivotal role in not only shaping but also operationalizing strategies that ensure successful product launches. With increasing competition and the growing complexity of the biopharma landscape, developing high-impact strategies and executing them seamlessly has become a cornerstone of launch excellence.

Best Practices, LLC undertook this study to provide actionable guidance on creating and implementing high-impact Medical Affairs launch strategies. The study focuses on leveraging data, advanced analytics, and digital tools to craft robust strategies while streamlining operational execution. It also explores how field medical teams and emerging technologies, such as AI and automation, can enhance strategic efficiency and elevate launch outcomes.

KEY TOPICS

Developing and Operationalizing High-Impact Medical Strategies for Launch Success
Leveraging Data, Advanced Analytics, and Digital Tools
Elevating Launch Impact through Field Medical Team Support
Driving Strategic Efficiency with AI and Automation

KEY METRICS

Involvement of Medical Affairs sub-functions in shaping and executing medical strategy
Top data sources for informing medical strategy
Medical strategy development timeline
Medical strategy meeting frequency with Directors and other strategy leads
Optimizing Medical Operations to drive successful medical launch strategy implementation
Top Medical Affairs-focused digital tools for tracking launch goals, KPIs, and insights
Leveraging AI and automation to optimize and streamline medical launch strategy development

SAMPLE KEY FINDINGS

Key Data Sources: Medical strategy is primarily built on three key sources of data and insights: 1) Clinical data, 2) Advisory boards, and 3) KOL feedback. Additionally, medical congresses, RWE, and competitive intelligence are vital sources for strategy development in many Medical Affairs groups.

METHODOLOGY

Best Practices, LLC engaged 18 Medical Affairs leaders driving launch, strategy, and operational excellence across top biopharma companies. Through benchmarking research and in-depth interviews with key benchmark partners, the study explores advanced insights and approaches for designing and implementing a successful medical launch strategy.

Industries Profiled:
Biotech; Pharmaceutical; Biopharmaceutical; Health Care; Clinical Research; Laboratories

Companies Profiled:
Chimerix; Corcept Therapeutics; Dermavant Sciences; Eisai; EMD Serono; Ferrer; Grifols; GlaxoSmithKline ; Galderma; Jazz Pharmaceuticals; KalVista Pharmaceuticals; Merz Aesthetics; OTSUKA; Sanofi; Santen; Takeda Pharmaceuticals; Vertex Pharmaceuticals; Zambon

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Interweaving Medical Strategy to Maximize New Treatment Success: Developing and Operationalizing Effective Launch Strategies

ID: 5842

Features:

Pages/Slides: 32

Published: 2024

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
688D1B5FCD527EA9300258BEA0034471E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-interweaving-medical-affairs-strategy-to-maximize-launch-success-developing-operationalizing-strategies?opendocument
18
19opendocument
2018.97.9.174
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB